Tumour cyclic AMP binding proteins and endocrine responsiveness in patients with inoperable breast cancer. by Watson, D. M. et al.
Br. J. Cancer (1987), 56, 141 142 1987
SHORT COMMUNICATION
Tumour cyclic AMP binding proteins and endocrine responsiveness in
patients with inoperable breast cancer
D.M.A. Watson, R.A. Hawkins, N.J. Bundred, H.J. Stewart & W.R. Miller
University Department ofClinical Surgery, Royal Infirmary, Lauriston Place, Edinburgh EH3 9 YW, UK.
The mere presence of oestrogen receptors (ER) is not a
reliable criterion for the response of mammary tumours to
endocrine therapy. While patients with undetectable levels of
tumour ER rarely respond to endocrine therapy, only 50-
60% of ER-positive human breast tumours regress following
hormone treatment (McGuire et al., 1975). There is,
therefore, a need to identify hormone dependent cancers
within the group of ER positive tumours.
In rat mammary tumours, a better assessment of hormone
dependency can be achieved by using the ratio of ER to
cyclic AMP binding proteins (cAMP BP) compared with
either parameter alone (Bodwin et al., 1980). The aim of this
study was to determine whether this ratio would also
improve prediction of response to endocrine therapy in
patients with advanced breast cancer.
Thirty-one women with ER-positive advanced breast
cancer were studied. Premenopausal patients with regular
menstrual periods (4 women) were treated by oophorectomy.
The remaining 27 postmenopausal patients (more than 2
years since their last menstrual period) received tamoxifen
(20mg/day) and/or aminoglutethimide (1 g/day) plus hydro-
cortisone (40mg/day) as primary endocrine treatment (except
for one patient who had previously received tamoxifen and
one women who had undergone a previous oophorectomy).
Response to treatment was classified according to UICC
criteria by an independent objective assessment of clinical
records and without knowledge of the results of the
biochemical analysis.
The biopsy material, which was obtained prior to
endocrine treatment, consisted of 26 primary tumours, 4
invaded lymph nodes and 1 mastectomy scar recurrence.
Cyclic AMP binding was determined as described previ-
ously (Miller et al., 1985) and the activity expressed on the
basis of cytosol protein which has been reported to reduce
intra-tumoral variation (Senbanjo et al., 1986). Concen-
tration of oestrogen receptors was determined (in a portion
of tumour adjacent to that taken for cAMP BP) by satura-
tion analysis (Hawkins et al., 1981). Activities in excess of
5 fmol mg- 1 cytosol protein were designated receptor
positive. Protein content of each cytosol was assayed by the
method of Bradford (1976) using bovine albumin as
standard.
Of 31 patients, 2 had a complete remission (CR), 12 a
partial remission (PR), 2 a static response (NC) and 15
progressive disease (PD). This represented an overall
response rate of 45% (CR+PR).
The level of ER in tumours, subdivided according to
response to endocrine therapy, is shown in Figure 1. Concen-
trations of ER were significantly higher in tumours from
responding patients as compared with those from the non-
responding group (P< 10-4, by Wilcoxon Rank Test) and
all responders had an ER level above lOOfmolmg-' protein.
However, one third of the patients whose tumour contained
ER in excess of lOOfmolmg-1 protein did not respond to
endocrine treatment.
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Figure 1 Levels of oestrogen receptors (ER), cyclic AMP
binding proteins (cAMP BP) and the ratio of ER to cAMP BP
in endocrine responsive (R) and non-responsive (NR) tumours.
Horizontal bars represent median values. Significance values are
derived from Wilcoxon Rank Test.
cAMP BP was detected in all tumours, with concen-
trations from 990 to 13,452fmolmg-' cytosol protein.
Levels of cAMP BP, subdivided into two groups according
to endocrine responsiveness, are shown in Figure 1. No
significant difference was observed between tumour cAMP
BP levels in responding and non-responding patients. The
ratio of ER to cAMP BP for each tumour within the
response groups is also presented in Figure 1. There was a
highly significant difference (P< 10-7) between the two
groups of patients. This difference was significantly greater
than that obtained by using ER alone, and it was possible to
discriminate totally between the patient groups. All subjects
responding to therapy had tumour ER/cAMP BP ratios
greater than 45 x 10-3 compared with non-responding
patients in whom values were less than this discriminatory
level.
These results show, as have others (Edwards et al., 1979;
Leclercq & Heuson, 1979), that patients with tumours having
a high concentration of ER are more likely to respond to
endocrine therapy than those with ER-poor tumours.
However, whilst a statistical difference in ER levels exists
between responding and non-responding groups, this does
not provide discrimination for individual patients. The
presence of progestogen receptors (PgR) in ER positive
tumours has been reported to improve the prediction of
endocrine responsiveness (Knight et al., 1975) but in the
present series of patients PgR did not enhance prediction.
(Of the 22 patients in which PgR was measured 5/8 PgR-
positive tumours and 6 of 14 PgR-negative tumours re-
sponded to treatment.) The presence of PgR, therefore, does
not necessarily improve the predictive value of ER.
Additional discriminating factors are clearly required.
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Evidence that cAMP BP may represent such a parameter
has come from studies in which regression of hormone-
dependent rat mammary tumours followed administration of
dibutyryl cAMP, the effect being apparently mediated by
cAMP BP (Cho-Chung & Redler, 1977). An inverse relation-
ship has also been described between the binding activities of
cAMP and oestrogen during growth and regression of rat
mammary tumours (Cho-Chung et al., 1978). cAMP BPs
appear to be a marker of tumour sensitivity to hormonal
manipulation, in that by using a ratio of tumour ER to
cAMP BP, Bodwin et al. (1980) were able to discriminate by
95% between hormone-dependent and independent rat
mammary tumours as compared with a value of 60% using
ER alone. A preliminary report from Kvinnsland ct al.
(1983) suggests that cAMP binding may also be of value in
human breast cancers. Results from our study support this
contention. Thus, the ratio of ER to cAMP completely
discriminated between responders and non-responders in
patients with ER-positive tumours. The cut-off point
between the two groups was 45 x 1O- which is different
from that used by Kvinnsland et al. (1983). However, the
methodology employed to measure cAMP BP was different
in the two studies and is likely to account for the dissimilar
ranges of values reported. It is necessary to emphasise that
in both studies patient numbers were small and
discriminatory levels have been decided retrospectively.
These observations require to be extended in a prospective
study using a predetermined cut-off point so that the useful-
ness of the ER to cAMP BP ratio in predicting endocrine
responsiveness can be confirmed.
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